Related Experiment Video
Updated: Oct 10, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
S16020 Pyridocarbazole Derivatives Display High Activity to Lung Cancer Cells
Gabriela Chabowska1, Helena Moreira1, Beata Tylińska2
1Department of Basic Medical Sciences, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.
Background:
Despite the dynamic development of medicine, globally cancer diseases remain the second leading cause of death. Therefore, there is a strong necessity to improve chemotherapy regimens and search for new anticancer agents. Pyridocarbazoles are compounds with confirmed antitumor properties based on multimodal mechanisms, i.e. DNA intercalation and topoisomerase II-DNA complex inhibition. One of them, S16020, displayed a wide spectrum of activity.
Objective:
The aim of the study was to investigate the antitumor potency of six S16020 derivatives, synthesized according to the SAR (structure-activity relationship) method.
Methods:
The biological evaluation included influence on cancer cell viability, proliferation, and migration, as well as P-glycoprotein activity. NHDF, A549, MCF-7, LoVo, and LoVo/DX cell lines were used in the study.
Results:
All derivatives displayed low toxicity to normal (NHDF) cells at 1 and 2 μM (≤ 20% of cell growth inhibition). The highest reduction in cell viability was noted in A549 cells, which was accompanied by significant disruption of cells proliferation and motility. Compound 1 exhibited the strongest cytotoxic, antiproliferative, and antimigratory effects, higher than the reference olivacine. A significant reduction in P-glycoprotein activity was found for derivatives 6 and 1.
Conclusion:
S16020 derivatives could be considered as potential candidates for new anticancer drugs.
Insights
New pyridocarbazole derivatives show promise as anticancer agents. Compound 1 demonstrated significant cytotoxic, antiproliferative, and antimigratory effects against cancer cells, offering potential for improved chemotherapy regimens.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Oncology
Background:
- Cancer remains a leading cause of death globally, necessitating novel chemotherapy agents.
- Pyridocarbazoles exhibit antitumor properties via DNA intercalation and topoisomerase II inhibition.
- The parent compound S16020 has demonstrated a broad spectrum of anticancer activity.
Purpose of the Study:
- To evaluate the antitumor potential of six novel S16020 derivatives.
- To assess the impact of structure-activity relationships (SAR) on derivative efficacy.
- To investigate effects on cancer cell viability, proliferation, migration, and P-glycoprotein activity.
Main Methods:
- Synthesis of six S16020 derivatives based on SAR principles.
- Biological evaluation using human normal dermal fibroblasts (NHDF) and cancer cell lines (A549, MCF-7, LoVo, LoVo/DX).
- Assessment of cytotoxicity, antiproliferative, antimigratory, and P-glycoprotein inhibitory effects.
Main Results:
- Derivatives showed low toxicity to normal NHDF cells at 1-2 μM.
- Significant reduction in viability, proliferation, and motility observed in A549 cells.
- Compound 1 exhibited superior cytotoxic, antiproliferative, and antimigratory effects compared to olivacine; compounds 1 and 6 reduced P-glycoprotein activity.
Conclusions:
- S16020 derivatives possess significant antitumor properties.
- Compound 1 is a particularly promising candidate for further anticancer drug development.
- These novel compounds warrant consideration as potential new therapeutic agents for cancer treatment.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...